The Zooxanthellate Jellyfish Holobiont Cassiopea andromeda, a Source of Soluble Bioactive Compounds
Marine Drugs · 2023
DOI: 10.3390/md21050272 ↗Kurz gefasst
Fachartikel in der Zeitschrift Marine Drugs, 2023. Verfasst von Stefania De Domenico und 5 weiteren Autor:innen. Beteiligte Einrichtung: Istituto di Scienze delle Produzioni Alimentari, Consiglio Nazionale delle Ricerche (CNR-ISPA, Lecce), 73100 Lecce, Italy. Hauptthemen laut MEDLINE: Cnidaria, Scyphozoa. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Recovery and Resilience Plan (NRRP), Apulian Region, Italy, European Commission.
Abstract (Originalsprache)
Cassiopea andromeda (Forsskål, 1775), commonly found across the Indo-Pacific Ocean, the Red Sea, and now also in the warmest areas of the Mediterranean Sea, is a scyphozoan jellyfish that hosts autotrophic dinoflagellate symbionts (family Symbiodiniaceae). Besides supplying photosynthates to their host, these microalgae are known to produce bioactive compounds as long-chain unsaturated fatty acids, polyphenols, and pigments, including carotenoids, with antioxidant properties and other beneficial biological activities. By the present study, a fractionation method was applied on the hydroalcoholic extract from two main body parts (oral arms and umbrella) of the jellyfish holobiont to obtain an improved biochemical characterization of the obtained fractions from the two body parts. The composition of each fraction (i.e., proteins, phenols, fatty acids, and pigments) as well as the associated antioxidant activity were analyzed. The oral arms proved richer in zooxanthellae and pigments than the umbrella. The applied fractionation method was effective in separating pigments and fatty acids into a lipophilic fraction from proteins and pigment–protein complexes. Therefore, the C. andromeda–dinoflagellate holobiont might be considered as a promising natural source of multiple bioactive compounds produced through mixotrophic metabolism, which are of interest for a wide range of biotechnological applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Istituto di Scienze delle Produzioni Alimentari, Consiglio Nazionale delle Ricerche (CNR-ISPA, Lecce), 73100 Lecce, Italy.
- Dipartimento di Scienze e Tecnologie Ambientali, Università del Salento, 73100 Lecce, Italy.
- Istituto di Nanotecnologia, Consiglio Nazionale delle Ricerche (CNR-NANOTEC), 73100 Lecce, Italy.
- Dipartimento Scienze della Terra e del Mare, Università degli Studi di Palermo, 90133 Palermo, Italy.
- Research Unit Lecce, Consorzio Nazionale Interuniversitario per le Scienze del Mare (CoNISMa), 73100 Lecce, Italy.
- National Biodiversity Future Center (NBFC), S.c.a.r.l., 90133 Palermo, Italy.
ORCID-Profile: Stefania De Domenico, Gianluca De Rinaldis, Stefano Piraino, Antonella Leone
Förderung
- National Recovery and Resilience Plan (NRRP)
- Apulian Region, Italy
- European Commission
- Horizon 2020 European Union’s Research and Innovation Program
- European Union—NextGenerationEU
- Apulian Region program “REFIN-Research for Innovation”
- EU project
Zitieren
APA
De Domenico, S., De Rinaldis, G., Mammone, M., Bosch-Belmar, M., Piraino, S., & Leone, A. (2023). The Zooxanthellate Jellyfish Holobiont Cassiopea andromeda, a Source of Soluble Bioactive Compounds. Marine Drugs. https://doi.org/10.3390/md21050272
Vancouver
De Domenico S, De Rinaldis G, Mammone M, Bosch-Belmar M, Piraino S, Leone A. The Zooxanthellate Jellyfish Holobiont Cassiopea andromeda, a Source of Soluble Bioactive Compounds. Marine Drugs. 2023. doi:10.3390/md21050272
BibTeX
@article{DeDomenico2023,
author = {De Domenico, Stefania and De Rinaldis, Gianluca and Mammone, Marta and Bosch-Belmar, Mar and Piraino, Stefano and Leone, Antonella},
title = {The Zooxanthellate Jellyfish Holobiont Cassiopea andromeda, a Source of Soluble Bioactive Compounds},
journal = {Marine Drugs},
year = {2023},
doi = {10.3390/md21050272}
}
EUVIMED